Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry
Diamant Thaci, Alan Menter, Jashin J Wu, Dilek Arikan, Hartmut Kupper, Mareike Bereswill, Wendell C Valdecantos
Abstract Not Available
Disclosures: Study supported by AbbVie.
psoriasis; adalimumab; biologic therapy
Abstract - 143 Poster PDF - 44
- There are currently no refbacks.